Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicare Price ‘Negotiation’ Process Gets Broad Brush Treatment In New Law

Executive Summary

With enactment of the drug pricing reform provisions in the Inflation Reduction Act, stakeholders now turn their attention to the implementing regulations that will be developed by the Centers for Medicare and Medicaid Services.

You may also be interested in...

Outgoing PhRMA Exec: Industry Needs To Better Tell Its Innovation Story

The brand drug industry’s success in tackling COVID-19 followed by swift political loss with the Inflation Reduction Act is in part due to the public’s continued knowledge gaps about the medical innovation ecosystem, outgoing PhRMA VP Jenny Bryant tells Pink Sheet in an interview.

Medicare Copay ‘Smoothing’ Plan Shows Nothing Is Simple In Part D

Guidance on how to implement a new policy to permit Part D beneficiaries to pay high copays in monthly installments (rather than all at once at the pharmacy counter) shows that there is no such thing as a straight-forward change in the drug benefit program.

Timetable For Medicare Price Negotiation Of The First 10 Drugs (And Beyond)

Manufacturers will face the beginning of a second round of price negotiation on Feb. 1, 2025, almost a year before prices from the first round go into effect. Dates for negotiating prices that are implemented in 2027 and in later years will follow a different schedule because the IRA built more time into the process for the first year.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts